Athenex Inc (ATNX) Stake Lowered by Northern Trust Corp

Northern Trust Corp decreased its holdings in shares of Athenex Inc (NASDAQ:ATNX) by 1.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 544,248 shares of the company’s stock after selling 9,411 shares during the quarter. Northern Trust Corp’s holdings in Athenex were worth $6,906,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of ATNX. Vanguard Group Inc boosted its stake in Athenex by 8.3% in the third quarter. Vanguard Group Inc now owns 1,878,063 shares of the company’s stock worth $29,185,000 after buying an additional 144,410 shares in the last quarter. Vanguard Group Inc. boosted its stake in Athenex by 8.3% in the third quarter. Vanguard Group Inc. now owns 1,878,063 shares of the company’s stock worth $29,185,000 after buying an additional 144,410 shares in the last quarter. BlackRock Inc. boosted its stake in Athenex by 3.2% in the third quarter. BlackRock Inc. now owns 3,582,578 shares of the company’s stock worth $55,673,000 after buying an additional 110,332 shares in the last quarter. Citigroup Inc. boosted its stake in Athenex by 146.8% in the fourth quarter. Citigroup Inc. now owns 129,927 shares of the company’s stock worth $1,649,000 after buying an additional 77,284 shares in the last quarter. Finally, Jaffetilchin Investment Partners LLC boosted its stake in Athenex by 16.7% in the fourth quarter. Jaffetilchin Investment Partners LLC now owns 191,132 shares of the company’s stock worth $2,425,000 after buying an additional 27,308 shares in the last quarter. 31.75% of the stock is owned by institutional investors.

NASDAQ:ATNX opened at $11.67 on Wednesday. The company has a market cap of $773.45 million, a PE ratio of -8.10 and a beta of 0.21. Athenex Inc has a fifty-two week low of $9.83 and a fifty-two week high of $20.90. The company has a quick ratio of 2.75, a current ratio of 3.31 and a debt-to-equity ratio of 0.36.

Athenex (NASDAQ:ATNX) last released its quarterly earnings data on Monday, March 11th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.21). The company had revenue of $21.27 million for the quarter. Athenex had a negative net margin of 131.81% and a negative return on equity of 66.23%. Sell-side analysts anticipate that Athenex Inc will post -1.75 earnings per share for the current year.

Several brokerages have issued reports on ATNX. BidaskClub lowered Athenex from a “hold” rating to a “sell” rating in a research note on Wednesday, April 3rd. SunTrust Banks started coverage on Athenex in a research note on Friday, March 29th. They issued a “buy” rating and a $20.00 target price for the company. Finally, Royal Bank of Canada reissued an “outperform” rating on shares of Athenex in a research note on Tuesday, March 12th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $20.00.

In other Athenex news, Director Song-Yi Zhang sold 32,240 shares of the stock in a transaction on Monday, March 11th. The stock was sold at an average price of $11.85, for a total value of $382,044.00. Following the completion of the transaction, the director now owns 4,000 shares in the company, valued at $47,400. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Sheldon Trainor-Degirolamo sold 54,085 shares of the stock in a transaction on Friday, March 15th. The stock was sold at an average price of $11.77, for a total value of $636,580.45. The disclosure for this sale can be found here. In the last three months, insiders have bought 57,500 shares of company stock valued at $696,090 and have sold 132,240 shares valued at $1,559,044. Corporate insiders own 29.50% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2019/04/17/athenex-inc-atnx-stake-lowered-by-northern-trust-corp.html.

About Athenex

Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform.

Read More: Intrinsic Value

Want to see what other hedge funds are holding ATNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Athenex Inc (NASDAQ:ATNX).

Institutional Ownership by Quarter for Athenex (NASDAQ:ATNX)

Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.